培门冬酶注射液联合CAG方案化疗方案用于加速期慢性粒细胞白血病患者的效果

Effects of Pegylated-L-asparaginase combined with CAG chemotherapy regimen on patients with accelerated phase chronic myeloid leukemia

目的:观察培门冬酶注射液联合CAG方案化疗方案用于加速期慢性粒细胞白血病(CML)患者的效果。方法:选取2021年3月至2023年2月该院收治的98例加速期CML患者进行前瞻性研究,按照随机数字表法将其分为观察组与对照组各49例。对照组给予CAG方案化疗,观察组在对照组基础上联合培门冬酶注射液治疗,比较两组临床疗效,治疗前后凝血功能指标水平、Th1/Th2淋巴细胞因子水平,以及不良反应发生率。结果:观察组治疗总有效率为73.47%,明显高于对照组的53.06%,差异有统计学意义(P<0.05);治疗后,两组纤维蛋白原、D-二聚体水平均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05);治疗后,两组血清白细胞介素(IL)-10、IL-4水平均低于治疗前,且观察组低于对照组,两组血清IL-2、γ干扰素水平均高于治疗前,且观察组高于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:培门冬酶注射液联合CAG方案化疗方案用于加速期CML患者可提高治疗总有效率,降低其纤维蛋白原、D-二聚体水平,改善其Th1/Th2淋巴细胞因子水平,效果优于单纯CAG方案化疗。

Objective:To observe effects of Pegylated-L-asparaginase combined with CAG chemotherapy regimen in patients with accelerated phase chronic myeloid leukemia(CML).Methods:A prospective study was conducted on 98 patients with accelerated phase CML admitted to this hospital from March 2021 to February 2023.According to the random number table method,they were divided into observation group and control group,49 cases in each group.The control group was given CAG chemotherapy,while the observation group was treated with Pegylated-L-asparaginase on the basis of that of the control group.The clinical efficacy,the coagulation function index levels,the Th1/Th2 lymphocyte factor levels before and after treatment,and the incidence of adverse reactions were compared between the two groups.Results:The total effective rate of treatment in the observation group was 73.47%,which was significantly higher than 53.06%in the control group,and the difference was statistically significant(P<0.05).After the treatment,the levels of fibrinogen and D-dimer in the two groups were lower than those before the treatment,those in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).After the treatment,the levels of serum interleukin(IL)-10 and IL-4 in the two groups were lower than those before the treatment,and those in the observation group were lower than those in the control group;the levels of serum IL-2 and interferon-γin the two groups were higher than those before the treatment,and those in the observation group were higher than those in the control group;and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Pegylated-L-asparaginase combined with CAG chemotherapy regimen can improve the total effective rate of treatment,reduce the levels of fibrinogen and D-dimer,and improve the levels of Th1/Th2 lymphocyte factors in the patients with accelerated phase CML.Moreover,it is superior to single CAG chemotherapy.